Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353765 · ClinicalTrials.gov registry record
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
A clinical trial of Locally Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen.
- Completed
- Registry status
- 247
- Enrollment target
- 1
- Study location
NCT04353765: Completed study of Locally Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen.
NCT04353765 is a study of Locally Advanced or Metastatic Renal Cell Carcinoma that has completed, run by Ipsen. The registered enrollment target is 247 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04353765, a study of Locally Advanced or Metastatic Renal Cell Carcinoma, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 247 participants
- Enrollment target
- 1
- Study location
Study Summary
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.
Conditions Studied
Interventions
- DRUG Cabozantinib monotherapy
- DRUG All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Study Locations (1)
Texas
- McKesson Life Sciences - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2020-06-05 |
What the finished NCT04353765 record still lists
NCT04353765 is an observational study that tracks outcomes without assigning an intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Locally Advanced or Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib monotherapy is the first listed.
NCT04353765 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04353765 about?
NCT04353765 is a clinical study titled "Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors". To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor ...
What is the current status of trial NCT04353765?
This trial is currently completed. The enrollment target is 247 participants. The study started on 2020-01-30. Estimated completion is 2020-06-05.
What conditions does trial NCT04353765 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT04353765?
The interventions under investigation include: Cabozantinib monotherapy (DRUG), All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC (DRUG).
Who is sponsoring clinical trial NCT04353765?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04353765 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI